Idarubicin
Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome
Fred Hutchinson Cancer CenterSmall moleculePhase 2/3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 64/ 100
- Competitive Position
- 81/ 100
Competitive context
74 Active assets in the Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYTARABINE National Cancer Institute (NCI) | Phase 3 | BBB |
Daunorubicin National Cancer Institute (NCI) | Phase 3 | BBB |
FILGRASTIM City of Hope Medical Center | Phase 2/3 | BBB |
ETOPOSIDE M.D. Anderson Cancer Center | Phase 3 | BB |
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Idarubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →